PRESS RELEASE: OCTOBER 2017
Australian Biotechnologies announces a new partnership with LifeHealthcare to provide clinical support and distribution for the Australian Biotechnologies Spinal Allograft Range.
LifeHealthcare Group Limited has today acquired the rights to provide clinical, in-hospital support for the Australian Biotechnologies Spinal Allograft Range, from Point Blank Medical Pty Ltd. The Directors of Point Blank Medical, Zack Khan and Ertan Ozer, will remain will remain involved over the next six months to ensure a smooth transition for their existing clients.
LifeHealthcare Chief Executive Officer, Matt Muscio, and Australian Biotechnologies Chief Executive Officer, Simon Berry, welcome the new partnership that ensures that Australian Spine Surgeons receive expanded clinical support, as Australian Biotechnologies releases the new AllovanceÒ Allograft Range, which includes 5 new bioactive specialty fusion allografts.
About Australian Biotechnologies
Australian Biotechnologies is the largest biological tissue processor in Australia producing over 20,000 bone and tissue allograft products annually. Working with key Australian Donation Partners our allografts offer life enhancing possibilities in orthopaedic, sports medicine, spine, foot and ankle, reconstructive trauma, oral and dental procedures. Headquartered in Sydney Australia and supplies allografts to Australia and New Zealand. For more information visit www.ausbiotech.com.au
LifeHealthcare Group Limited is a leading independent provider of healthcare solutions in Australia and New Zealand across clinically specialised therapeutic channels bringing Australian and New Zealand healthcare professionals innovative medical devices by partnering with world class companies who share the vision of innovation and making a real difference to people’s lives. For more information, visit www.lifehealthcare.com.au
Please try again
To change the password, click the link in the email.
Please log in.
Please log in.
Do you realy want to delete the item?